Columbia University is one of twenty-five type 1 diabetes TrialNet International Clinical Centers at the forefront of type 1 diabetes research. Led by Robin Goland, MD, the TrialNet team at Columbia University is dedicated to preventing type 1 diabetes and stopping disease progression by preserving insulin production before and after diagnosis.
Dr. Robin Goland, J. Merrill Eastman Professor of Clinical Diabetes, Professor of Medicine and Pediatrics at Columbia University, directs the patient care and clinical research programs at the Berrie Center. She was instrumental in establishing the Naomi Berrie Diabetes Center in July 1998. Under the leadership of Dr. Goland and Berrie Center Co-Director Dr. Rudolph Leibel, the Berrie Center has become recognized nationally and internationally for excellence and innovation in patient care and research in diabetes. Dr. Goland has a B.A. from Harvard University and an M.D. from Columbia University College of Physicians & Surgeons. She was a resident and chief medical resident at NY-Presbyterian Hospital and did her endocrinology research training at Columbia University.
Sarah Pollak, RN
Elizabeth Robinson, RN
If you have a relative with T1D, you may be eligible for risk screening that can detect the early stages of T1D years before symptoms appear. More
Depending on your risk screening results, you may be eligible for monitoring. We’ll monitor you for disease progression and let you know if you become eligible for a study. More
We are testing the drug hydroxychloroquine (HCQ) to see if it can delay or prevent early stage T1D (stage 1) from progressing to abnormal glucose tolerance (stage 2) and ultimately prevent clinical diagnosis (stage 3). HCQ is already used to reduce symptoms and progression of other autoimmune diseases, such as rheumatoid arthritis and lupus. This is the first study to see if it can prevent or delay T1D. Details
TrialNet is testing the drug abatacept to see if it can delay or prevent progression of early stage T1D (stage 1 or stage 2), and ultimately prevent clinical diagnosis (stage 3). In earlier studies for people newly diagnosed (stage 3), abatacept helped slow down disease progression. Details
If you are diagnosed with T1D while participating in one of our prevention studies, we’re still here for you. You can continue to receive personal monitoring while helping us learn more. More